{
    "eid": "2-s2.0-85128160115",
    "title": "Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection",
    "cover-date": "2022-04-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Microbiology (medical)",
            "@code": "2726",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Ed J. Gane",
        "Christian Schwabe",
        "Elina Berliba",
        "Pisit Tangkijvanich",
        "Alina Jucov",
        "Nelea Ghicavii",
        "Thierry Verbinnen",
        "Oliver Lenz",
        "Willem Talloen",
        "Thomas N. Kakuda",
        "Chris Westland",
        "Megha Patel",
        "Jeysen Z. Yogaratnam",
        "Leonard Dragone",
        "Pieter Van Remoortere"
    ],
    "citedby-count": 3,
    "ref-count": 24,
    "ref-list": [
        "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance",
        "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection",
        "Hepatitis B cure: from discovery to regulatory approval",
        "In vitro antiviral activity and mode of action of JNJ-64530440, a novel potent hepatitis B virus capsid assembly modulator in clinical development",
        "A first-in-human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly, following single-and multiple-ascending-oral-dose studies with or without ritonavir in healthy adult volunteers",
        "Antiviral activity and pharmacokinetics of the HBV capsid assembly modulator GLS4 in patients with chronic HBV infection",
        "A five-in-one first-in-human study to assess safety, tolerability, and pharmacokinetics of RO7049389, an inhibitor of hepatitis B virus capsid assembly, after single and multiple ascending doses in healthy participants",
        "RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated",
        "Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379",
        "JNJ-64530440, a novel capsid assembly modulator: single-and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers",
        "Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest\u00ae ) and elastography (FibroScan\u00ae )",
        "Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B",
        "JNJ-56136379, an HBVcapsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection",
        "Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136397 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro",
        "Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial",
        "Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection",
        "Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants",
        "Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus",
        "Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency",
        "Ideal cure for hepatitis infection: the target is in sight",
        "Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy",
        "Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients",
        "Pharmacokinetics and antiviral activity of the capsid inhibitor AB-506 in healthy subjects and chronic hepatitis B subjects"
    ],
    "affiliation": [
        {
            "affiliation-city": "Chisinau",
            "@id": "60071302",
            "affilname": "Nicolae Testemitanu State University of Medicine and Pharmacy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071302",
            "affiliation-country": "Moldova"
        },
        {
            "affiliation-city": "Beerse",
            "@id": "60068574",
            "affilname": "Janssen Pharmaceutica, Headquarters",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60068574",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Titusville",
            "@id": "60027736",
            "affilname": "Janssen Pharmaceuticals, Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60027736",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Auckland",
            "@id": "60005686",
            "affilname": "The University of Auckland",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005686",
            "affiliation-country": "New Zealand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "San Francisco",
            "@id": "122846115",
            "affilname": "Janssen Biopharma",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122846115",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Auckland",
            "@id": "100814963",
            "affilname": "Auckland Clinical Studies",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100814963",
            "affiliation-country": "New Zealand"
        },
        {
            "affiliation-city": "Chisinau",
            "@id": "100602516",
            "affilname": "Republican Clinical Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100602516",
            "affiliation-country": "Moldova"
        }
    ],
    "funding": [
        "Janssen Biopharma",
        "Janssen Global Services"
    ]
}